Title Alternative | Epidemiological characteristics of novel coronavirus infection in Okayama Prefecture |
---|---|
FullText URL | 133_43.pdf |
Author | Higashionna, Tsukasa| Sendo, Toshiaki| Kusano, Nobuchika| Tsukahara, Hirokazu| |
Keywords | 疫学的調査 (epidemiological characteristics) 岡山 (Okayama Prefecture) 新型コロナウイルス感染症 (COVID-19) PCR検査 (PCR testing) SARS-CoV-2 |
Publication Title | Journal of Okayama Medical Association |
Published Date | 2021-04-01 |
Volume | volume133 |
Issue | issue1 |
Start Page | 43 |
End Page | 48 |
ISSN | 0030-1558 |
Related Url | isVersionOf https://doi.org/10.4044/joma.133.43 |
language | Japanese |
Copyright Holders | Copyright (c) 2021 岡山医学会 |
File Version | publisher |
DOI | 10.4044/joma.133.43 |
NAID | 130008034824 |
Title Alternative | Drug interaction (50. Drug interaction mediated transporters) |
---|---|
FullText URL | 133_68.pdf |
Author | Manabe, Yohei| Esumi, Satoru| Sendo, Toshiaki| |
Publication Title | Journal of Okayama Medical Association |
Published Date | 2021-04-01 |
Volume | volume133 |
Issue | issue1 |
Start Page | 68 |
End Page | 72 |
ISSN | 0030-1558 |
Related Url | isVersionOf https://doi.org/10.4044/joma.133.68 |
language | Japanese |
Copyright Holders | Copyright (c) 2021 岡山医学会 |
File Version | publisher |
DOI | 10.4044/joma.133.68 |
NAID | 130008034821 |
JaLCDOI | 10.18926/AMO/63410 |
---|---|
FullText URL | 76_2_167.pdf |
Author | Higashionna, Tsukasa| Ushio, Soichiro| Esumi, Satoru| Murakawa, Kiminaka| Kitamura, Yoshihisa| Sendo, Toshiaki| |
Abstract | Febrile neutropenia (FN) is a serious side effect in patients undergoing cancer chemotherapy and frequently proves fatal. Since infection control is crucial in the management of FN, the antimicrobial agent cefozopran (CZOP) has been recommended but not approved for routine use in clinical care of FN in Japan. However, few studies of CZOP in the management of FN have used a thrice daily dose schedule. The aim of this study was to retrospectively compare the efficacy and safety of CZOP at a dose of 1 g three times daily to those of cefepime (CFPM) in the treatment of FN in our lung cancer patients. The response rates of the CZOP and CFPM groups were 89.5% (17/19 cases) and 83.0% (39/47 cases), respectively, with no significant difference between the two groups. The median duration of antimicrobial treatment was 6 days (4-10 days) in the CZOP group and 7 days (3-13 days) in the CFPM group, with no significant difference between groups. The incidence rates of adverse events were 21.1% (4/19 cases) in the CZOP group and 19.1% (9/47 cases) in the CFPM group. No adverse events of Grade 3 or higher were observed in either group. The findings of the present study suggest that CZOP administration at a dose of 1 g three times per day as an antimicrobial treatment alternative against FN. |
Keywords | febrile neutropenia cefozopran cefepime lung cancer retrospective |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2022-04 |
Volume | volume76 |
Issue | issue2 |
Publisher | Okayama University Medical School |
Start Page | 167 |
End Page | 172 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | Copyright Ⓒ 2022 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 35503444 |
Web of Science KeyUT | 000792374900008 |
FullText URL | fulltext.pdf |
---|---|
Author | Ushio, Soichiro| Wada, Yudai| Nakamura, Mizuki| Matsumoto, Daiki| Hoshika, Kota| Shiromizu, Shoya| Iwata, Naohiro| Esumi, Satoru| Kajizono, Makoto| Kitamura, Yoshihisa| Sendo, Toshiaki| |
Keywords | anxiolytic inflammation immunomodulation macrophages Kampo medicine |
Published Date | 2022-08-12 |
Publication Title | Frontiers In Pharmacology |
Volume | volume13 |
Publisher | Frontiers Media S.A. |
Start Page | 890048 |
ISSN | 1663-9812 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2022 Ushio, Wada, Nakamura, Matsumoto, Hoshika, Shiromizu, Iwata, Esumi, Kajizono, Kitamura and Sendo. |
File Version | publisher |
PubMed ID | 36034871 |
DOI | 10.3389/fphar.2022.890048 |
Web of Science KeyUT | 000860773600001 |
Related Url | isVersionOf https://doi.org/10.3389/fphar.2022.890048 |